Cargando…
Corrigendum: Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma via the combination therapy with FOXM1 inhibitor RCM1
Autores principales: | Donovan, Johnny, Deng, Zicheng, Bian, Fenghua, Shukla, Samriddhi, Gomez-Arroyo, Jose, Shi, Donglu, Kalinichenko, Vladimir V., Kalin, Tanya V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135300/ https://www.ncbi.nlm.nih.gov/pubmed/37124500 http://dx.doi.org/10.3389/fonc.2023.1163510 |
Ejemplares similares
-
Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma via the combination therapy with FOXM1 inhibitor RCM1
por: Donovan, Johnny, et al.
Publicado: (2023) -
FOXM1 nuclear transcription factor translocates into mitochondria and inhibits oxidative phosphorylation
por: Black, Markaisa, et al.
Publicado: (2020) -
Lung endothelial cells regulate pulmonary fibrosis through FOXF1/R-Ras signaling
por: Bian, Fenghua, et al.
Publicado: (2023) -
FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
por: Milewski, David, et al.
Publicado: (2021) -
Expression of Foxm1 Transcription Factor in Cardiomyocytes Is Required for Myocardial Development
por: Bolte, Craig, et al.
Publicado: (2011)